Durability of Adalimumab and Infliximab in Children With Crohn's Disease: A Nationwide Comparison From the epi-IIRN Cohort.

Ohad AtiaChagit FrissGili FochtRamit Magen RimonNatan LeddermanAmir Ben-TovYiska Loewenberg WeisbandEran MatzYuri GorelikYehuda ChowersIris DotanDan Turner

Published in: Inflammatory bowel diseases (2024)

Our results support using adalimumab monotherapy as a first-line biologic in children with CD. When infliximab is used, combotherapy may be advantageous over monotherapy.

Keyphrases

rheumatoid arthritis
ulcerative colitis
young adults
combination therapy
juvenile idiopathic arthritis
open label
cross sectional
clinical trial
disease activity
systemic lupus erythematosus